Our findings indicate that engineering oHSV to express a full-length anti-CD47 antibody, especially the IgG1 version, with locoregional delivery is a promising and non-toxic approach to enhance oncolytic virotherapy of GBM. This evidence concerns the gene CD47 and glioblastoma.